Auro Laboratories Limited - Due diligence report

A 360° intelligence report on Auro Laboratories: trust score, financial health, credit view, compliance, directors, growth and distress sign…

1989-05-26 Thane, Maharashtra Active Listed Active Compliant
Share
AL Auro Laboratories Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Auro Laboratories — 360° Intelligence Report

Generated from MCA filings & public records
76/100
Trust Score
Low Risk

Auro Laboratories is assessed as Low Risk with a Trust Score of 76/100. Auro Laboratories is an active public limited indian non-government company incorporated in 1989, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Auro Laboratories Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
40/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (BBB-).

Charges position: 2 open (68.00 cr) · 13 satisfied (11.97 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Indian Bank4 48.0 cr
Allahabad Bank9 48.0 cr
Indian Overseas Bank1 48.0 cr
The Maharashtra State Financial Corporation1 48.0 cr
Compliance Score: 40/100 Caution Indicated
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Flagged by authority: BSE.
  • Litigation present in 4 court forum(s).
  • 2 auditor resignation(s) filed - latest: KHURDIA JAIN & CO on 2023-07-31.
  • 1 active GST registration(s).
Legal cases on record (4)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
KIRAN SURESH KULKARNI 01234567 Director 01/04/2018 6 yrs Approved
Mahendra Kumar Daga 01234567 Director 01/04/2018 6 yrs Approved
SIDDHARTHA DEORAH 01234567 Director 01/04/2018 6 yrs Approved
VISHAL KAILASHCHANDRA JHUNJHUNWALA 01234567 Director 01/04/2018 6 yrs Approved
SHARAT DEORAH 01234567 Director 01/04/2018 6 yrs Approved
KAVITA VIJAYAKANT SHARMA 01234567 Director 01/04/2018 6 yrs Approved
Kuntal Prafulchandra Pancholi 01234567 Director 01/04/2018 6 yrs Approved
  • 7 directors on the board.
  • No disqualified or deactivated DINs.
  • 3 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a majority stake - exact percentages are part of the full report.

Key managerial personnel: KIRAN SURESH KULKARNI (Whole-time director) · SIDDHARTHA DEORAH (Whole-time director) · SHARAT DEORAH (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 80
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 37+ years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
Compliance score is weak (40/100).
2 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
4 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence63/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment72/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 68.00 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view84/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
19 Nov 2025
Charge satisfied
Indian Bank
25 Sep 2025
Last AGM held
Annual general meeting
11 Aug 2025
Charge satisfied
Indian Bank
21 Jul 2025
Charge created
Indian Bank - 1.80 cr
12 Jun 2025
Director appointed
Kuntal Prafulchandra Pancholi (Cfo)
31 Mar 2025
Latest balance sheet
Filed with ROC
21 Mar 2025
Charge created
Indian Bank - 1.80 cr
27 Jun 2024
Director ceased
Mahendra Kumar Daga
01 Apr 2024
Director appointed
Mahendra Kumar Daga (Director)
29 Feb 2024
Charge created
Indian Bank - 20.00 Lakh
01 Oct 2023
Director ceased
AMIT MAHIPAT SHAH
22 Sep 2023
Director ceased
VISHAL KAILASHCHANDRA JHUNJHUNWALA
23 Aug 2023
Director appointed
VISHAL KAILASHCHANDRA JHUNJHUNWALA (Director)
24 May 2021
Director appointed
KIRAN SURESH KULKARNI (Whole-time director)
Director ceased
KIRAN SURESH KULKARNI
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
7 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB- from Crisil.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Biozenta Lifescience U74999MH2018PTC440022 Mumbai, Maharashtra, India
Sanjivani Parentral L24300MH1994PLC081752 Mumbai, Maharashtra, India
Finozol Speciality Chemicals Private Limited U24290MH2019PTC330295 Navi Mumbai, Maharashtra, India
Cu-V-Kar Genetic Medicine Private Limited U02423TN2007PTC061947 Chennai, Tamil Nadu, India
Rv Lifesciences Limited U24230MH1991PLC063442 Aurangabad, Maharashtra, India
Pharmanza (India) U24230GJ2009PTC055895 Khambhat, Gujarat, India
Kausikh Therapeutics U24232TN2000PTC044776 Gerugambakkam, Tamil Nadu, India
Asoj Soft Caps U24110MH1981PTC024872 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Auro Laboratories before audits and certifications: compliance score 40/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Auro Laboratories: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Auro Laboratories - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Auro Laboratories pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Auro Laboratories - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Auro Laboratories an active company?

Auro Laboratories has MCA status “Active” with a compliance score of 40/100 (Caution Indicated).

Is Auro Laboratories financially healthy?

Auro Laboratories has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Auro Laboratories?

Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Auro Laboratories?

Promoters hold a majority stake - exact percentages are in the full report. 7 active director(s) are on record.

Does Auro Laboratories have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 13 earlier charge(s) stand satisfied.

Is Auro Laboratories up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 40/100 (Caution Indicated).

Is it risky to lend to Auro Laboratories?

Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.